A large-scale clinical trial conducted within the Department of Veterans Affairs indicates that analyzing a patient’s genetic makeup can assist medical providers in avoiding antidepressants that may be difficult for the body to process. Patients who underwent this pharmacogenomic testing were more likely to be prescribed medications with fewer predicted negative interactions. Additionally, these patients experienced a modest but statistically significant improvement in the remission of their depression symptoms compared to those receiving standard care. The findings of this research were published in the Journal of the American Medical Association. Major depressive disorder is a pervasive and debilitating health condition that affects millions of adults. Symptoms often include persistent sadness, loss of interest in activities, insomnia, changes in appetite, and in severe cases, thoughts of suicide. Finding the right medication to manage these symptoms is frequently a challenge. Current clinical practice largely relies on a trial-and-error approach, where a patient tries a medication for several weeks to see if it works. If the first drug fails or causes intolerable side effects, the patient and doctor …